5 result(s) displayed (1 - 5 of 5):

Bristol-Myers maintains strategy with OTC sale (from Corporate Dealmaker)

In Bristol-Myers Squibb Co.'s (NYSE: BMS) bid to morph from a traditional drugmaker into a focused biopharma, the firm sold over-the-counter assets in Asia-Pacific (excluding China and Japan) to Taisho Pharmaceutical Co. Ltd. for $160 million. Bristol also sold its 97.8% stake in PT Bristol-Myers Squibb Indonesia Tbk to Taisho...

Posted on September 16, 2009 9:57 AM

Bristol-Myers: Inside ConvaTec carveout (from Corporate Dealmaker)

Under CEO James Cornelius Bristol-Myers Squibb Co. (NYSE: BMS) has made major changes to its portfolio of businesses, en route to changing itself from a diversified healthcare company into a more tightly focused biopharma. We've noted many of the steps along the way, such as the February spinoff of Mead-Johnson...

Posted on May 5, 2009 9:44 AM

Cash-rich Bristol-Myers wants to buy, not sell (from Corporate Dealmaker)

Bristol-Myers Squibb Co. said its net earnings for the third quarter increased to about $2.6 billion from $858 million in the previous year's period. The New York-based pharma giant now has about $7.2 billion cash on hand, too. In a conference call, chairman and CEO James Cornelius said "we have a long list of companies, compounds, technologies we'd like to acquire over the next couple...

Posted on October 24, 2008 12:18 PM

Bristol-Myers continues to morph with Kosan buy (from Corporate Dealmaker)

Drug developer Bristol-Myers Squibb Co. made another deal as it tries to focus on its pharmaceutical business, paying a 233% premium for cancer therapeutics company Kosan Biosciences. Bristol is paying $190 million cash hoping Kosan's late-stage drug Hsp90, among others, will come to market and bring in a few hundred...

Posted on May 30, 2008 7:56 AM

Bristol-Myers taps dealmaker as new CFO (from Corporate Dealmaker)

On March 31, Andrew Bonfield, executive vice president and chief financial officer of Bristol-Myers Squibb Co., will relinquish his role to Jean-Marc Huet. Huet (pictured) comes to BMS from the world of baby food. He was the engineer behind Amsterdam-based Royal Numico NV's acquisition strategy and their eventual $16.8 billion...

Posted on March 5, 2008 12:08 PM